A ranar 5 ga Yuli, Novo Nordisk ya ƙaddamar da gwajin gwaji na asibiti na kashi III na allurar CagriSema a kasar Sin, manufarsa ita ce kwatanta aminci da ingancin allurar CagriSema tare da semeglutide a cikin marasa lafiya masu kiba da kiba a China.
CagriSema allurar magani ce mai tsayi mai tsayi a ƙarƙashin haɓaka ta Novo Nordisk, manyan abubuwan haɗin gwiwa sune GLP-1 (glucagon-like peptide-1) agonist mai karɓar smeglutide da amylin analog cagrilintide mai tsayi.Ana iya yin allurar CagriSema sau ɗaya a mako.
Manufar farko ita ce kwatanta CagriSema (2.4 mg/2.4 MG) tare da semeglutide ko placebo sau ɗaya a mako-mako.Novo Nordisk ya sanar da sakamakon gwajin CagriSema don maganin ciwon sukari na 2, wanda ya tabbatar da cewa tasirin hypoglycemic na CagriSema ya fi na semeglutide, kuma kusan 90% na batutuwa sun cimma burin HbA1c.
Bayanan sun nuna cewa ban da tasirin hypoglycemic mai mahimmanci, dangane da asarar nauyi, allurar CagriSema ta fi semeglutide (5.1%) da cagrilintide (8.1%) tare da asarar nauyi na 15.6%.
Sabuwar maganin Tirzepatide shine farkon yarda da GIP/GLP-1 agonist na mako-mako na duniya.Yana hada tasirin incretins guda biyu a cikin kwayoyin halitta guda daya wanda ake allura sau daya a mako kuma sabon nau'in jiyya ne na nau'in ciwon sukari na 2.Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da Tirzepatide a watan Mayu 2022 don inganta sarrafa glycemic (a kan tsarin abinci da motsa jiki) a cikin manya masu fama da ciwon sukari na 2 kuma a halin yanzu an amince da su a cikin Tarayyar Turai, Japan da sauran ƙasashe.
A ranar 5 ga Yuli, Eli Lilly ya sanar da wani lokaci na III SURPASS-CN-MONO binciken kan rajistar gwajin gwaji na asibiti da dandamalin bayyana bayanan don kula da masu ciwon sukari na 2.SURPASS-CN-MONO wani bincike ne na bazuwar, makafi biyu, nazari na lokaci-lokaci na III wanda aka tsara don kimanta inganci da amincin tirzepatide monotherapy idan aka kwatanta da placebo a cikin mutanen da ke da nau'in ciwon sukari na 2.Binciken ya yi niyyar haɗawa da marasa lafiya 200 masu ciwon sukari na 2 waɗanda ba su da kowane magungunan antidiabetic a cikin kwanaki 90 kafin Ziyarar 1 (sai dai a wasu yanayi na asibiti, kamar rashin lafiya mai tsanani, asibiti, ko tiyata na zaɓi, ɗan gajeren lokaci (≤14) kwanaki) yin amfani da insulin).
Ana sa ran za a amince da nau'in ciwon sukari na 2 a wannan shekara
A watan da ya gabata, an buga sakamakon binciken SURPASS-AP-Combo a ranar 25 ga Mayu a cikin mujallar Nature Medicine.Sakamakon ya nuna cewa idan aka kwatanta da glargine na insulin, Tirzepatide ya nuna mafi kyawun HbA1c da raguwar nauyi a cikin yawan masu ciwon sukari na 2 a yankin Asiya-Pacific (yafi China): raguwar HbA1c har zuwa 2.49% da raguwar nauyi har zuwa 7.2 kg. (9.4%) a cikin makonni 40 na jiyya, babban ci gaba a cikin lipids na jini da hawan jini, da kuma cikakken aminci da haƙuri suna da kyau.
Gwajin asibiti na mataki na 3 na SURPASS-AP-Combo shine binciken farko na Tirzepatide da aka gudanar musamman a cikin marasa lafiya na kasar Sin masu fama da ciwon sukari na 2, wanda Farfesa Ji Linong na asibitin jama'a na jami'ar Peking ya jagoranta.SURPASS-AP-Combo ya yi daidai da sakamakon jerin bincike na SURPASS na duniya, wanda ya kara tabbatar da cewa ilimin halittar jiki na ciwon sukari a cikin marasa lafiya na kasar Sin ya yi daidai da na marasa lafiya a duniya, wanda shine tushen bincike na lokaci guda tare da samar da sababbin magunguna. a kasar Sin da ma duniya baki daya, kuma yana ba da kwakkwaran shaida don baiwa majinyatan kasar Sin damar yin amfani da sabbin magungunan maganin ciwon sukari da aikace-aikacensu na asibiti a kasar Sin da wuri-wuri.
Lokacin aikawa: Satumba 18-2023